Hypercapnic encephalopathy syndrome: A new frontier for non-invasive ventilation?  by Scala, Raffaele
Respiratory Medicine (2011) 105, 1109e1117ava i lab le at www.sc iencedi rec t .com
journa l homepage: www.e lsev ier .com/ locate / rmedREVIEW
Hypercapnic encephalopathy syndrome: A new
frontier for non-invasive ventilation?Raffaele Scala*U.O. Pneumologia e Unita` di Terapia Semi-Intensiva Respiratoria, AUSL 2, Campo di Marte Hospital, Lucca, Italy
Received 22 October 2010; accepted 7 February 2011
Available online 26 February 2011KEYWORDS
Non-invasive
ventilation;
Hypercapnic
encephalopathy;
Endotracheal
intubation;
Acute respiratory
failure;
Respiratory intensive
care unit;
Sedation* Via Lorenzetti, 9, 52100 Arezzo, It
E-mail address: raffaele_scala@ho
0954-6111/$ - see front matter ª 201
doi:10.1016/j.rmed.2011.02.004Summary
According to the classical international guidelines, non-invasive ventilation is contraindicated
in hypercapnic encephalopathy syndrome (HES) due to the poor compliance to ventilatory
treatment of confused/agitated patients and the risk of aspirative pneumonia related to lack
of airways protection. As a matter of fact, conventional mechanical ventilation has been re-
commended as “golden standard” in these patients.
However, up to now there are not controlled data that have demonstrated in HES the advan-
tage of conventional mechanical ventilation vs non-invasive ventilation. In fact, patients with
altered mental status have been systematically excluded from the randomised and controlled
trials performed with non-invasive ventilation in hypercapnic acute respiratory failure. Recent
studies have clearly demonstrated that an initial cautious NPPV trial in selected HES patients
may be attempt as long as there are no other contraindications and the technique is provided
by experienced caregivers in a closely monitored setting where ETI is always readily available.
The purpose of this review is to report the physiologic rationale, the clinical feasibility
and the still open questions about the careful use of non-invasive ventilation in HES as first-line
ventilatory strategy in place of conventional mechanical ventilation via endotracheal
intubation.
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“Hypercapnic encephalopathy syndrome” (HES) is a hetero-
geneous and potentially reversible wide spectrum of neuro-
logical alterations (from cognitive defects, psychomotor
agitation and confusion with asterixis to soporous status,
delirium and coma) occurring in the presence of acute
respiratory failure (ARF) with severe decompensated respi-
ratory hypercapnic acidosis.1,2
Patho-physiology of HES is not fully understood as its
clinicalmanifestations arenot always clearly connectedwith
PaCO2 levels and several pulmonary and extra-pulmonary
factors are involved.1e7 The mechanism which may better
explain HES is dependent on the acidosis of cerebrospinal
fluid and of brain interstitial tissue (Table 1, Fig. 1).4,5 Acute
respiratory acidosis has a greater impact on liquor pH than
metabolic acidosis; in fact, differently from hydrophilic
bicarbonate ions, CO2 passes very quickly through the hae-
mato-encephalic barrier because of its high liposolubility.5
Accordingly, symptoms of HES are correlated stronger with
the changes in cerebrospinal pH than with those of arterial
pH and/or PaCO2.
1e5 The role played by both hypoxaemia
and non-controlled oxygen-therapy (i.e. high inspiratory
oxygen fractions (FiO2)) may be not irrelevant (Fig. 1).
8,9
From the clinical point of view, none of the three most
common used neurological scores have been validated to
assess HES severity: Glasgow coma scale (GCS), encephalop-
athy score (ES), KellyeMatthay scale (KMS) (Table 2).10e12
Although GCS is the tool which has been mostly used in the
clinical practice, this 15-point scoring system was originally
built to assess and monitor changes in the level of
consciousness occurring after head injury.10 ES is a 4 level-
scale which was introduced by Brochard et al.11 to assess
neurological dysfunctions in patients with hypercapnic ARF;
the main limitation of this tool is the lack of specificity and
clarity (i.e. same level of scale for different consciousnesse 1 Pathogenetic mechanisms of Hypercapnic Encephalopa
Intra-cranic hypertension secondary to vasodilatation of resi
Cerebrospinal fluid and brain tissue acidosis with:
increased cerebral blood flow and oedema
lower levels of cerebral phosphocreatine
higher lactate/pyruvate ratio, higher cerebral levels of gluco
Krebs cycle metabolism of carbohydrates
increased aminoacids metabolism with higher cerebral levels
Cerebral hypoxia due to arterial systemic hypoxemia
Rebound effect of high FiO2 on PaCO2 and pH from: hypoven
ventilation/perfusion ratio; Haldane effect
Neurotropic drugs (i.e. benzodiazepines, opioids)
Impaired cardiovascular and renal function
Alterations of hydro-electrolytic balance
Primitive coexistent cerebral diseases (i.e. chronic atheroscdisturbances). The 6-level KMS is the only tool which was
specifically designed to evaluate neurological alterations in
patients ventilated in Intensive Care Unit (ICU)12 and who has
been recently shown to have a prognostic value in HES
patients treated with non-invasive positive pressure ventila-
tion (NPPV) in a Respiratory High-Dependency Unit (RHDU).13
NPPV has reached the highest level of scientific evidence
as first-line ventilatory technique to treat episodes of ARF
occurring in COPD exacerbations, cardiogenic pulmonary
oedema, immunosuppressed patients and during the tran-
sition from invasive ventilation to spontaneous breathing.14
Conversely, the effectiveness of NPPV in other acute
diseases (e.g. pneumonia and acute lung injury) and in
specific clinical conditions (e.g. patients with impairment
of sensorium and/or difficulty in removing secretions) has
not still been demonstrated.14
This paper is an up-date of the role of non-invasive
ventilation to treat HES; alterations of consciousness due to
primitive neurological diseases (e.g. stroke) and to other
metabolic/toxic causes are excluded.Ventilatory strategies in hypercapnic
encephalopathy
Management of HES should be based on: 1) close monitoring
in units with an adequate level of expertise (i.e. ICU,
RHDU); 2) “etiologic treatment” towards the precipitating
condition (i.e. pneumonia, COPD exacerbation, heart
decompensations) plus “controlled oxygen-therapy” (e.g.
to avoid PaCO2 rebound by an injudicious use of O2) 3)
mechanical ventilation to quickly correct gas exchange and
neurological status; 4) “protection of airways” in patients
without efficient cough to prevent pulmonary infections
(i.e. “ab ingestis” and bronchial mucous retention); 5)
“control” of psychomotor agitation which may occur atthy Syndrome.
stance cerebral arteries
se-6-phosphate and fructose-6-phosphate with impaired
of ammonium and glutamine
tilation due to suppressed hypoxic stimulus drive; altered
lerotic encephalopathy)
Figure 1 Pathogenesis of Hypercapnic Encephalopathy Syndrome. CBF: cerebral blood flow; CSF: cerebrospinal fluid; ICP: intra-
cranic pressure; V/Q: ventilation/perfusion ratio.
Non-invasive ventilation in hypercapnic encephalopathy 1111either the onset of HES episode or during the “awaking
phase” of a comatose patient.2
According to the Consensus Conference, international
reviews and states of the art, NPPV is contraindicated in
HES (i.e. GCS < 10), while endotracheal intubation (ETI) is
recommended and, therefore, conventional mechanical
ventilation (CMV) considered the “golden standard” venti-
latory strategy.15,17 These statements are based on bothTable 2 Clinical tools for the assessment of neurological impai
Glasgow Coma Scale (GCS)
Eyes open (E) Verbal response (V)
Spontaneously (4 p.) Oriented (5 p.)
To verbal stimulation (3 p.) Confused (4 p.)
To painful stimulation (2 p.) Inappropriate words (3 p.)
No open (1 p.) Incomprehensible sounds (2 p.)
No response (1 p.)
GCS Z E þ V þ M; range from 3 (worst neurological impairment)
Encephalopathy score (ES)
Grade 0 Z normal
Grade 1 Z hypertonia or cogwheel rigidity without an abnorm
Grade 2 Z tremor, asterixis, or daytime sleepiness
Grade 3 Z confusion or agitation
Grade 4 Z prostration or vigil coma
KellyeMatthay score (KMS)
Grade 1 Z alert, follows complex 3-step command
Grade 2 Z alert, follows simple commands
Grade 3 Z lethargic, but arousable and follows simple comma
Grade 4 Z stuporous (only intermittently follows simple comm
Grade 5 Z comatose, brain stem intact
Grade 6 Z comatose with brain stem dysfunctionthe poor/lack compliance to NPPV of confused/agitated
HES patients and the risk of aspirative pneumonia related
to NPPV-induced gastro-distension, weak cough and lack of
airways protection. Moreover, some clinical studies identi-
fied neurological impairment as a negative prognostic
factor for NPPV outcome.18e21
However, up to now there are not controlled data that
have demonstrated the advantage of CMV vs NPPV in HES. Inrment in critically ill patients.
Motor response (M)
Obey verbal command (6 p.)
Localises pain (5 p.)
Defend from painful stimulus (4 p.)
Decorticate rigidity (3 p.)
Decerebrate rigidity (2 p.)
No response (1p.)
to 15 points (normal sensorium)
ality in consciousness
nds
ands even with vigorous attempts to arouse the patient)
1112 R. Scalafact, patients with altered mental status have been
systematically excluded from the randomised controlled
trials (RCTs) performed with NPPV in hypercapnic ARF.22,23
Moreover, some observational studies have not confirmed
that HES is a negative predictor for NPPV success.24e29
Conversely, some points are in favour of the rationale
employ of NPPV in HES:
1) the similar efficacy of NPPV vs CMV in terms of unloading
respiratory muscles, gas exchanges improvement and in-
hospital mortality in severely acidotic COPD patients in
whom mechanical ventilation is mandatory30e33;
furthermore, the application of non-invasive negative
pressure ventilation via iron lung (ILV) has turnout tobeas
effective as CMV in severe hypercapnic ARF34;
2) the reduced risk of ventilator associated pneumonia
(VAP) with NPPV in place of CMV to treat ARF due to the
avoidance of endotracheal tube and the less number of
invasive devices35,36; moreover, an RCT demonstrated
the usefulness of NPPV in severe community-acquired
pneumonia (CAP) occurring in COPD patients37;
3) the physiologic barrier of the upper and lower oesopha-
geal sphincters (respectively tone of 40 and 32 cm H2O)
against the risk of gastro-distension during NPPV38,39;
4) the role of NPPV as “ceiling therapy” or as “tool to buy
time in the end-of-life decisions” in HES patients with
“end-of stage” chronic respiratory disorders40e43;
5) the reduced costs of treating COPD patients without
multi-organ failure (MOF) in RHDU vs ICU.44
Non-invasive ventilation in hypercapnic
encephalopathy: where we are?
Thefirst and larger trial on theuseof non-invasive ventilation
in HES is the retrospective study of Corrado et al.45 con-
ducted in an RHDU with iron lung applied to 150 cases of
hypoxaemicehypercapnic coma with severe acidosis. The
authors reported ILV success in avoiding ETI of 70% and an
hospital mortality of 24% with a quick sensorium recover
(median time Z 4 h). The outcome resulted stratified
depending on HES severity, being worst for GCS  5. Only 5
patients developed pulmonary aspiration, but all of them
survived. Unfortunately, ILV is available in few centres which
have acquired a great experience with this ventilatory
technique.
The majority of data are about non-invasive ventilation
in HES patients reported the use of NPPV delivered via nasal
and full-face mask.
ThefirstattemptofusingNPPV inHES is found inBenhamou
et al. study,25 where nasal NPPV succeeded in 60% of ARF
patients, most of them showing an altered level of
consciousness [24/30]; specifically, two out of 3 cases with
a GCS Z 3 were responsive to NPPV. Then, only few case
reports and clinical series including a limited number of HES
patients treated with NPPV were published.24,26e29 More
recently, some non-RCTstudies3,46e49 have demonstrated the
feasibilityofNPPVto successfully treatHESpatients (Table3).
In a prospective uncontrolled ICU Spanish study, Diaz
et al.46 compared theefficacy ofNPPVapplied via facialmask
to 95 patients with GCS  8 vs that achieved in 863 patients
with GCS > 8. Surprisingly, the rate of NPPV success wasslightly but significantly greater in comatose than in non-
comatose patients (80% vs 70.1%; p Z 0.0434) without
significant difference in-hospital mortality (26.3% vs 33.2%;
p > 0.05). Moreover, 1 h of NPPV quickly and significantly
improved blood gases, diastolic pressure and sensorium in
comagroup,with quick normalisation ofmental status (mean
timeZ 4.1 h) in 85.3% of cases. By applying the multivariate
analysis, GCS after 1 h of NPPV and the degree of MOF at ICU
admission were the only parameters which independently
predicted NPPV failure. The main limitation of the study is
the heterogeneous distribution of the diseases between the
two groups: compared to GCS > 8 group, GCS  8 group
showed a greater prevalence of more NPPV-responsive
diseases, like COPD (69.5% vs 25.5%), respect to that of
disorders in whom the likelihood of NPPV success is lower, as
CAP or ARDS (8.4% vs 22.5%).
In the second case-control prospective Italian study per-
formed in an RHDU, Scala et al.3 analysed the outcome of
NPPV in three groups of COPD patients in ARF with different
degrees of HES (mild, KMSZ 2; moderate, KMSZ 3; severe,
KMS > 3) compared to that of a control group with a normal
sensorium (KMS Z 1), strictly matched in terms of several
clinicalephysiological parameters. After 1e2 h of NPPV the
authors reported a significant improvement of blood gases
and KMS in all groups. Rates of NPPV failure, in-hospital and
90-days post-dischargemortality were progressively worst as
much severe was the degree of HES reaching the significance
only between the KMS > 3 and the control group. Among the
causes leading to NPPV failure, only cardiovascular compli-
cations were significantly greater in the KMS > 3 vs the
control group, in accordance with the negative effects of
acidosis upon myocardial inotropism and excitability50 and
with theprognostic impact of cardiovascular comorbidities in
COPD exacerbations needing NPPV.51 Conversely, the
number of treatment failures due to an inefficient removal of
secretions was similar among all groups without cases of
aspirative pneumonia.Theauthors hypothesised that the risk
of aspiration might have been minimised by the quick
improvement of neurological status under NPPV.
In the third case-control study performed in a Chinese
RHDU, Zhu et al.47 did not report aworst outcomeofNPPV via
face mask (ETI and hospital mortality) in a group of 22 COPD
patients with GCS< 10 vs a control group of 21 subjects with
GCS  10, even though pressure support, NPPV time and
RHDU length of stay were significantly higher in the former
group.
Very recently, in a case-control study Scala et al.48
compared the hospital outcomes of 20 patients with COPD
exacerbations and moderate-severe HES (i.e. KMS  3)
managed by NPPV in an RHDU vs that of 20 COPD subjects
(strictly matched for age, SAPS II, arterial blood gases)
managed by CMV in an ICU. Gas exchange significantly
improved after 2 h in both groups. In-hospital mortality, one-
yearmortality and tracheostomy ratewere similar in the two
groups, while complication rate (p Z 0.027) was lower in
NPPV-groupdue to fewer cases of nosocomial pneumonia and
sepsis. NPPV-group showed also a shorter duration of venti-
lation (p Z 0.009) than CMV-group. The authors suggested
that, despite some limitations of their study (no-RCT design;
different settings of care), an initial cautious NPPV trial in
patientswithCOPDexacerbations andHESmaybeattempt as
long as there are no other contraindications and the
Table 3 Clinical studies of non-invasive ventilation in Hypercapnic Encephalopathy Syndrome.
Author, year Type of study Setting Patients/COPD pH PaCO2(mmHg) PaO2/FiO2 Sensorium level Need of
ETI (%)
Hospital
mortality (%)
Corrado, 1996 Retrospective (ILV) RHDU 150/118 7.13 112 43.6a GCS  8 30 24
Corrado, 2004 RCT (ILV vs CMV) RHDU 22/22 7.20 96 192 GCS Z 14 (3e15)c 18.2 18.2
Benhamou, 1992 Open, prospective ICU 30/20 7.29 65 44a Altered in 60% 40 47
Fernandez, 1993 Open, prospective ICU 14/14 7.19 92 98a Altered 21 7
Carlucci, 2001 Multicenter Prospective ICU 36/NA 7.35b 56b 214b ES  1 53 NA
Conti, 2002 RCT (NPPV vs CMV) ICU 23/23 7.20 85 168 KMS Z 3 (5)d 52 26
Duen˜as-Pareja, 2002 Open, prospective RW 13/10 7.18 92 203 GCS  7 31 31
Confalonieri, 2005 Multicenter Prospective ICU, RHDU, RW 1033/1033 7.28 80.4 180 GCS Z 13.2 (2.3)d 22.8 13.7
Diaz, 2005 Open, prospective ICU 95/66 7.13 99 139 GCS Z 6.5 (1.7)d 24 25
Scala, 2005 Case-control RHDU 20/20 7.28 79.3 164 KMS Z 2 25 25
Scala, 2005 Case-control RHDU 20/20 7.26 81.9 170 KMS Z 3 30 20
Scala, 2005 Case-control RHDU 20/20 7.22 91.1 154 KMS > 3 45 45
Honrubia, 2005 RCT (NPPV vs CMV) ICU 31/20 7.27 72.0 119 KMS Z 3e5e in 58% 58 32
Zhu, 2007 Case-control RHDU 43/43 7.18 102 168 GCS Z 7.5 (1.9)d 27.3 13.6
Scala, 2007 Case-control (NPPV vs CMV) RHDU 20/20 7.22 88.2 162 KMS Z 3-5e 35 25
Claudett, 2008 Case-control (NPPV vs CMV) ED 12/12 7.18 75.3 103a GCS Z 5.6 (1.3)d 16.7 16.7
Scala, 2010 Case-control (NPPV vs CMV) RHDU 15/15 7.27 76.0 163 KMS Z 3.4 20 20
ILV Z Iron lung ventilation; NPPV Z non-invasive positive pressure ventilation; COPD Z chronic obstructive pulmonary disease; CMV Z conventional mechanical ventilation;
RCT Z randomized controlled trial; NA Z not available; GCS Z Glasgow Coma Scale; KMS Z KellyeMatthay Scale; ES Z Encephalopathy Score; ICU Z Intensive Care Unit;
RHDU Z Respiratory High-Dependency Unit; ED Z Emergency Department; RW Z Respiratory Ward; ETI Z endotracheal intubation.
a PaO2 (mmHg).
b Arterial blood gases in all 108 patients submitted to NPPV, with and without hypercapnic encephalopathy.
c Mean (range).
d Mean (standard deviation).
e Range.
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1114 R. Scalatechnique is provided by experienced caregivers in a closely
monitored setting where ETI is always readily available.
Similarly, in the second case-control study performed in
a South-American Emergency Department (ED) comparing
NPPVvsCMV in treatingHESpatients, Claudett et al.49 did not
report any differences in the clinical outcomes of the studied
24 patients. It has to be remarked the high mean values of
PaO2 (about 100 mmHg) in the population which suggested
that an inadequate O2-therapy may have contribute to HES
development; thus may have overestimated the NPPV
success.
The comparability of the findings of the different studies
about the application of NPPV in HES is difficult to be
performed, due to the heterogeneity in the severity of
altered level of consciousness, in the typology of the po-
pulation recruited (underlying diseases, comorbidities,
arterial blood gases), in the setting and in the modality of
treatment. Concerning the type of the treated respiratory
disorders, the majority of the available data in favour of
the successful use of NPPV in HES are referred to COPD
exacerbations. This is in accordance with the experience of
Phua et al.52 who clearly showed that in a multivariate
analysis the likelihood of NPPV failure is significantly
greater in non-COPD compared to COPD patients.
Another confounding factor is the different clinical tool
chosen in the published studies to assess the level of neuro-
logical dysfunction. The degree of HES as measured by the
three available systems (GCS, ES, KMS)10e12 cannot be
compared due to the different way to assess mental
impairment that was used by each one. It may be believed
that for highest levels of dysfunction which identify the
condition of “hypercapnic coma” (i.e. GCS < 8, ES > 3,
KMS>4) the chanceofNPPV success is substantially reduced.
Its should be underlined that in these studies NPPV was
applied almost continuously in the first 24e48 h till the
recovery of alertness and the improvement in blood gases.
The “integrated use” of ILV and NPPV is likely to expand
the success in HES patients, as suggested by the “real
world” study in whom the need of ETI was strongly reduced
in a large series of patients with exacerbations of chronic
respiratory disorders.53
It’s important to highlight that a great deal of these data
on the success of non-invasive ventilation in patients with
altered mental status were achieved in centres (ICU and
RHDU) with a good experience in NPPV and/or ILV,54
a strong motivation for non-invasive techniques of moni-
toring and of ventilatory support, an immediate access to
CMV and a quick management of complications occurring in
critical patients.Drawbacks for non-invasive ventilation in
hypercapnic encephalopathy
The first limitation for the feasibility and the success of
NPPV in HES is the lack of co-operation in agitated patients
who could not cope with the mask and the pressurised air
pushed by the ventilator.14 Despite the assistance provided
by an experienced nurse team, severe patient-ventilator
asynchrony, major air leaks and patient’s attempts in
removing the interface may make impossible for the
physician to provide an adequate NPPV therapy leaving asthe only option the assistance with CMV under heavy
pharmacological sedation.
Concerning the problem of psychomotor agitation and the
possibility of using pharmacologic sedation to increase the
compliance to NPPV in HES, a recent multi-centre survey55
demonstrated that a large majority of the physicians infre-
quently used sedation andanalgesic therapy (<25%of cases),
even though practices varies depending on geographic
regions (North America higher vs Europe) and speciality
(critical care specialists higher vs pulmonologists). The most
common used drugs were lorazepam (North America) and
morphine (Europe). The setting and the nurse-patient ratio
influenced the choice of using sedation during NPPV in this
survey, suggesting that only a closemonitoringmay allow this
practice “safely” preventing the risk of a respiratory
depression. So far some pilot studies56e59 reported the
feasibility of different sedations during NPPV in poor/lack
cooperative patients to increase the success of the ventila-
tory technique. However, before its routine implementation
in the clinical ground, this topic need to be further investi-
gated due to the fact that the risk-benefit balance of this
practice depends on the environment, the experience of the
team, the type of drug and the patient’s status.
Another important drawback for the successful use of
NPPV in HES patients with a depress cough reflex is the
inefficacy to spontaneously clear airways from an excessive
burden of respiratory secretions3,14e18,31,48; this is essen-
tially due to the kinds of interfaces used to deliver NPPV,
which do not allow direct access into the airways. Conse-
quently, the inability to spontaneously remove respiratory
secretions has been considered a contraindication to start
NPPV in ARF, especially in patients with impaired
consciousness and depressed cough.14e17
Few published data suggested that some non-invasive
physiotherapeutic techniques may improve mucous clear-
ance in COPD exacerbations managed with NPPV.60e62
Unfortunately, no data are available with these techniques
in patients with HES and abundant restagnant secretions.
Recently, in the clinical scenario of patients with COPD
decompensations who require ETI and CMV because of
impaired mucous clearance and HES, Scala et al.63 postu-
lated that the early suction of secretions with fiberoptic
bronchoscopy (FBO) performed during NPPV is feasible and
may also allow for the successful expanded application of
NPPV. This thesis was supported by the feasibility and
safety of performing a diagnostic FBO with broncho-alve-
olar lavage (BAL) for a suspected pneumonia under NPPV in
patients with either hypoxaemic or hypercapnic ARF.64e69
In a matched case-control study Scala et al.63 compared
15 acutely decompensated COPD patients with copious
secretion retention and HES due to CAP undergoing early
FBO plus BAL during NPPV in an expert RHDU with 15
controls (matched for blood gases, APACHE III score, KMS,
pneumonia extension and severity) receiving CMV in the
ICU. Two hours of NPPV plus FBO significantly improved
ABGs, sensorium and cough efficiency without major
complications (cardiovascular events, emergent ETI,
pneumothorax). Improvement in PaCO2 and pH, as well as
hospital mortality, and durations of hospitalisation and
ventilation were similar in NPPV vs CMV-groups. NPPV
significantly reduced serious infectious complications
compared with CMV, as well as the need for tracheostomy
Figure 2 Hypothesis of a therapeutic management of Hypercapnic Encephalopathy Syndrome. GCS: Glasgow coma scale; KMS:
KellyeMatthay scale; NPPV: Non-invasive positive pressure ventilation; ETI-CMV: Endotracheal intubation-conventional mechanical
ventilation; FBO: fiberoptic bronchoscopy; ABG: arterial blood gases; ICU: Intensive care unit; RHDU: respiratory high-dependency
unit.
Non-invasive ventilation in hypercapnic encephalopathy 1115(p < 0.05). Even if this NPPV strategy may be a successful
alternative to CMV to manage selected COPD patients
within expert units, the authors acknowledged for some
potential limitations of their study (case-control design
without randomisation, different settings of treatment of
the two groups, applicability of the data only to units with
a large expertise on NPPV and FBO). Larger RCTs are
necessary to confirm this preliminary result and, therefore,
to test the efficacy of the FBOeNPPV protocol applied to an
earlier time-course of COPD decompensations when ETI
is not mandatory by comparing NPPV alone vs NPPV with
early FBO.
Conclusions
Due to the lack of protection of airways, non-invasive
ventilation is traditionally not recommended in HES while
CMV is considered the “gold-standard”. However, recent
literature data have demonstrated that the risk of pulmo-
nary aspiration and the likelihood of NPPV ineffectiveness
are surely overestimated in HES. According to these
preliminary results obtained in few motivated centres,
a cautious attempt of NPPV/ILV seems to be justified in
selected COPD patients with HES provided that it’s per-
formed by an high experienced team with a close
monitoring and prompt availability of CMV (Fig. 2). Giventhe fact that these published data may be not replicated in
units with lower degree of expertise and lower intensity of
care, so far a large-scale application of NPPV to treat HES is
not routinely recommended. Furthermore, an unduly delay
in prompt intubating patients with severe ARF-related
altered consciousness, may increase the risk of serious
systemic complications and, eventually, of death. As
a matter of a fat, further large-scale controlled studies are
needed to confirm these data about the feasibility and
success of NPPV/ILV in HES and, therefore, to clarify the
role of sedation and FBO-based strategy to overcome the
drawbacks occurring during NPPV in this series of patients.
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